Cargando…
Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics
Neuroblastoma serves as a paradigm for applying tumor genomic data for determining patient prognosis and thus for treatment allocation. MYCN status, i.e., amplified vs. non-amplified, was one of the very first biomarkers in oncology to discriminate aggressive from less aggressive or even favorable c...
Autores principales: | Ambros, Inge M., Brunner, Clemens, Abbasi, Reza, Frech, Christian, Ambros, Peter F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129917/ https://www.ncbi.nlm.nih.gov/pubmed/25161957 http://dx.doi.org/10.3389/fonc.2014.00202 |
Ejemplares similares
-
Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors
por: Brunner, Clemens, et al.
Publicado: (2016) -
Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses
por: Abbasi, M. Reza, et al.
Publicado: (2014) -
Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression
por: Rifatbegovic, Fikret, et al.
Publicado: (2017) -
The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016) -
Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
por: Schriegel, Felix, et al.
Publicado: (2021)